Collagen
Also known as: Hydrolyzed collagen, Collagen peptides, Collagen hydrolysate, Type I collagen, Type II collagen, Bovine collagen, Marine collagen, Fish collagen, Chicken collagen, Eggshell membrane collagen, Collagen booster
This ingredient is classified as unclassified risk (GIRI score: 1.5/10).
Safety Profile
Known Safety Concerns
- Vegan labeling conflict (all standard collagens are animal-derived); allergen risk (fish/bovine/chicken/egg depending on source); gummy dose far below clinically effective range
Contraindications
- Vegan labeling conflict (all standard collagens are animal-derived); allergen risk (fish/bovine/chicken/egg depending on source); gummy dose far below clinically effective range
Interactions
Information not yet available for this ingredient profile.
Evidence and Scientific Findings
Ingredient Overview
Collagen is the most abundant structural protein in mammals (~30% of total body protein), providing tensile strength to skin, tendons, ligaments, bone, and cartilage. Supplemental forms include: Type I (skin, tendons, bone — from bovine hide, marine/fish skin, eggshell membrane); Type II (articular cartilage — from bovine/chicken sternal cartilage); Type III (blood vessels, skin — from bovine). Hydrolyzed collagen peptides (di- and tripeptides) are absorbed intact, stimulate fibroblast collagen synthesis via Pro-Hyp/Hyp-Gly peptide signalling, and distribute to skin dermis. Effective supplemental doses in clinical trials: 2,500–10,000 mg/day for skin elasticity and hydration; 5,000–10,000 mg/day for nail and hair outcomes. Gummy format typically delivers 100–500 mg collagen per serving — substantially below clinically studied doses; document this limitation. Vitamin C is the essential cofactor for endogenous collagen cross-linking. VEGAN LABELING CONFLICT: All standard supplemental collagens (bovine, porcine, marine fish, chicken, eggshell) are animal-derived and CANNOT be used in genuinely Vegan-labeled products. If a product claims both Vegan and Collagen: either (1) it uses a plant-based “collagen booster” (amino acid precursors: glycine, proline, hydroxyproline + Vitamin C supporting endogenous collagen synthesis — NOT exogenous collagen), or (2) it is a labeling error. Must be clarified on product label — document which scenario applies. Allergen flags depending on source: FISH (marine collagen), BOVINE, CHICKEN, EGG. Generally safe; rare gastrointestinal discomfort (bloating, loose stools) at high doses. Avoid in shellfish/fish allergy if marine collagen source.
Biological and Chemical Classification
Information not yet available for this ingredient profile.
Mechanism of Action
Information not yet available for this ingredient profile.
Clinical Evidence of Effectiveness
Information not yet available for this ingredient profile.
Pharmacokinetics
Information not yet available for this ingredient profile.
Recommended Dosage
Information not yet available for this ingredient profile.
SETI — Scientific Evidence Transparency Index
Executive Summary — Ingredient Assessment
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or RCT)
- Main clinical benefit observed: Specialty
- Evidence consistency: High consistency across studies (100%)
- Vegan labeling conflict (all standard collagens are animal-derived); allergen risk (fish/bovine/chicken/egg depending on source); gummy dose far below clinically effective range
The available scientific evidence for Collagen indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.
Total SETI Score
High risk| Evidence quality | 10/40 |
| Evidence consistency | 20/20 |
| Safety signals | 0/20 |
| Study recency | 10/10 |
| Evidence transparency | 10/10 |
Evidence Summary
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or systematic review)
- 0 studies identified benefits or no safety concern (GREEN)
- 10 studies reported limited or advisory safety evidence (YELLOW)
Evidence Policy
Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.
Last updated: 06 აპრ 2026, 12:09
Evidence Distribution
-
Observational / other LOW evidence YELLOWOMICS Profiling Identifies Signatures of Senescence in Osteogenesis Imperfecta Osteoblasts Counteracted by 4-PBA. ↗Besio R et al.. OMICS Profiling Identifies Signatures of Senescence in Osteogenesis Imperfecta Osteoblasts Counteracted by 4-PBA.. J Cell Mol Med. 2026. PMID:41937492.PMID 41937492 ↗Journal J Cell Mol MedYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41937492/
-
Observational / other LOW evidence YELLOWPolydatin Relieves Airway Remodeling by Inhibiting P2X7R-NLRP3-Mediated Excessive Autophagy in Asthma. ↗Li G et al.. Polydatin Relieves Airway Remodeling by Inhibiting P2X7R-NLRP3-Mediated Excessive Autophagy in Asthma.. Immun Inflamm Dis. 2026. PMID:41937438.PMID 41937438 ↗Journal Immun Inflamm DisYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41937438/
-
Observational / other LOW evidence YELLOWInterplay of Skin Aging: Mitochondrial Stress and Ultraviolet Exposure. ↗Liao W et al.. Interplay of Skin Aging: Mitochondrial Stress and Ultraviolet Exposure.. Photodermatol Photoimmunol Photomed. 2026. PMID:41937223.PMID 41937223 ↗Journal Photodermatol Photoimmunol PhotomedYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41937223/
-
Observational / other LOW evidence YELLOWHyaluronic acid-poly (vinyl alcohol) composite hydrogels with self-assembled peptide nanofibers as Bruch's membrane mimics for age-related macular degeneration treatment. ↗Bagewadi S et al.. Hyaluronic acid-poly (vinyl alcohol) composite hydrogels with self-assembled peptide nanofibers as Bruch's membrane mimics for age-related macular degeneration treatment.. Int J Biol Macromol. 2026. PMID:41937011.PMID 41937011 ↗Journal Int J Biol MacromolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41937011/
-
Observational / other LOW evidence YELLOWDe novo antiglomerular basement membrane Goodpasture syndrome in a liver transplant recipient: balancing autoimmunity, allograft protection, and infection risk. ↗Solanki S et al.. De novo antiglomerular basement membrane Goodpasture syndrome in a liver transplant recipient: balancing autoimmunity, allograft protection, and infection risk.. Clin Transplant Res. 2026. PMID:41936570.PMID 41936570 ↗Journal Clin Transplant ResYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41936570/
-
Observational / other LOW evidence YELLOWEpigallocatechin Gallate as an Anti-Fibrotic Agent. ↗Tarahovsky YS et al.. Epigallocatechin Gallate as an Anti-Fibrotic Agent.. Biochemistry (Mosc). 2026. PMID:41936557.PMID 41936557 ↗Journal Biochemistry (Mosc)Year 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41936557/
-
Observational / other LOW evidence YELLOWEwsr1a Regulates the Development of the Axial Skeleton in Zebrafish. ↗Merkes C et al.. Ewsr1a Regulates the Development of the Axial Skeleton in Zebrafish.. Zebrafish. 2026. PMID:41936538.PMID 41936538 ↗Journal ZebrafishYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41936538/
-
Observational / other LOW evidence YELLOWPedunculoside ameliorates liver fibrosis by targeting c-Jun to inhibit hepatic stellate cell activation. ↗Wang A et al.. Pedunculoside ameliorates liver fibrosis by targeting c-Jun to inhibit hepatic stellate cell activation.. Int Immunopharmacol. 2026. PMID:41936306.PMID 41936306 ↗Journal Int ImmunopharmacolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41936306/
-
Observational / other LOW evidence YELLOWIntegrative Nanotechnology and Biomaterial Approaches for Targeted Diabetic Wound Regeneration. ↗Kolay A et al.. Integrative Nanotechnology and Biomaterial Approaches for Targeted Diabetic Wound Regeneration.. Curr Diabetes Rev. 2026. PMID:41936106.PMID 41936106 ↗Journal Curr Diabetes RevYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41936106/
-
Observational / other LOW evidence YELLOWStudy on the selective oxidation of tapioca starch via a two-step method and its application in titanium tanning. ↗Li W et al.. Study on the selective oxidation of tapioca starch via a two-step method and its application in titanium tanning.. Int J Biol Macromol. 2026. PMID:41935807.PMID 41935807 ↗Journal Int J Biol MacromolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41935807/
Score Transparency
0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.
Method: Q = number of approved references ÷ 10 (capped at 1.0)
Limited — mostly case reports or animal studies
Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.
Mixed or neutral — roughly equal benefit and risk signals
Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.
One or more monitoring-level safety signals active
Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.
Final GIRI Score for Collagen. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
Full methodology & data sources
The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.
- References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
- Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
- Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
- Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
Risk Level Classification
Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.
0–3.0
3.0–5.5
5.5–7.5
7.5–10
The score pin shows exactly where this ingredient falls on the fixed risk scale.
What drove the Low classification for Collagen
A score of 1.5 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
0 approved references.
Limited — mostly case reports or animal studies (Level 4–5).
Neutral or mixed — benefit and risk signals roughly balanced.
No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.
No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).
How are the Low / Moderate / High / Critical thresholds defined?
The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:
| Level | Score | Meaning |
|---|---|---|
| LOW | 0.0 – 2.9 | Sparse or predominantly beneficial evidence. No active safety alerts. |
| MODERATE | 3.0 – 5.4 | Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups. |
| HIGH | 5.5 – 7.4 | Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended. |
| CRITICAL | 7.5 – 10 | Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision. |
Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.